Revolutionary Dual Therapy for Late-Stage Cancer: Tiny Particles Deliver Heat and Chemotherapy

**MIT researchers have developed novel microparticles designed to deliver a dual therapy — heat and chemotherapy — directly to tumors, potentially offering new treatment options for late-stage cancer patients.** Traditional chemotherapy often brings significant side effects and limited effectiveness. In contrast, this innovative approach aims to target tumors more precisely and may reduce adverse reactions by administering chemotherapy locally rather than intravenously. **The technology involves using a material called molybdenum sulfide as a phototherapeutic agent** that effectively converts laser light into heat. This allows for the use of low-power lasers to heat the particles. By combining molybdenum disulfide with either hydrophilic or hydrophobic chemotherapy drugs, researchers created microparticles that can be implanted into tumor sites. Once administered, **an external near-infrared laser activates the particles, initiating the photothermal treatment and releasing chemotherapy agents by melting a polymer matrix within the microparticles.** Remarkably, **in mice studies, tumors were completely eradicated, and the subjects' survival time was significantly extended** compared to those treated with chemotherapy or phototherapy alone. The polymer used in the particles, polycaprolactone, is FDA-approved, paving the way for potential human clinical trials. The research indicates this treatment could be particularly beneficial for fast-growing tumors where current options are limited, offering the possibility of **improved control over tumor growth and enhanced quality of life for patients.** The team, led by Ana Jaklenec, Angela Belcher, and Robert Langer, alongside former MIT postdoc Maria Kanelli, envision applications across various solid tumors, including metastatic cases. **This study represents a promising advancement in cancer treatment, potentially revolutionizing approaches to combat late-stage cancer.**